[Multi-gene expression profiling tests to assess recurrence risk in early-stage breast cancer patients]
Magron A
Record ID 32018014404
French
Original Title:
Tests de profilage d’expression multigénique pour évaluer le risque de récidive chez les personnes atteintes d’un cancer du sein précoce
Authors' objectives:
The Institut national d'excellence en santé et en services sociaux (INESSS) was
mandated by the Ministère de la Santé et des Services sociaux (MSSS) to conduct a
brief review of the scientific literature on multi-gene expression profiling tests for breast
cancer, following up on its previous work published in 2018.
Authors' results and conclusions:
RESULTS : Analysis of the most recent data on multi-gene expression profiling tests revealed the
following:
• the survival rate of post-menopausal women with node-negative or 1-3 nodepositive breast cancer who received an intermediate recurrence score with
Oncotype DX was shown to be similar, regardless of whether they received
adjuvant chemotherapy in combination with hormone therapy, up to 9 years after
treatment. This suggests that chemotherapy may not offer additional benefits in
recurrence-free survival in this group of women; •there is currently a lack of comparative data assessing the ability of different tests
to predict recurrence risk in hormone-dependent HER2- breast cancer patients. •The guidelines identified in this work report that :
• the use of multi-gene expression profiling tests is recommended as an additional
tool to support clinicians in making decisions regarding adjuvant chemotherapy in
post-menopausal women with early-stage breast cancer RH+ and HER2-, either
node-negative or with 1-3 positive lymph nodes;
• the use of these tests is not recommended for women with 4 positive lymph nodes
or more, due to insufficient supporting evidence
Authors' methods:
An exploratory review of literature data published since 2018 was conducted to provide
an overview of the current use of multi-gene expression profiling tests both internationally
and in Quebec.
Authors' identified further research:
The upcoming publication of data from the OPTIMA trial, expected in 2026, will provide
further evidence on the predictive value of select multi-gene expression profiling tests. INESSS continues to track new data published on the subject, which could lead to
updates of its work.
Details
Project Status:
Completed
Year Published:
2025
URL for published report:
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/tests-de-profilage-dexpression-multigenique-pour-evaluer-le-risque-de-recidive-chez-les-personnes-atteintes-dun-cancer-du-sein-precoce.html
English language abstract:
An English language summary is available
Publication Type:
Other
Country:
Canada
Province:
Quebec
MeSH Terms
- Breast Neoplasms
- Gene Expression Profiling
- Prognosis
- Neoplasm Recurrence, Local
Contact
Organisation Name:
Institut national d'excellence en sante et en services sociaux
Contact Address:
L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name:
demande@inesss.qc.ca
Contact Email:
demande@inesss.qc.ca
Copyright:
L'Institut national d'excellence en sante et en services sociaux (INESSS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.